Evidence map›Paper›PMID 30090215›Full record

ArticleAvicenna journal of medical biotechnology

Neslihan Edeer Karaca, Ezgi Ulusoy Severcan, Burcu Guven, Elif Azarsiz, Guzide Aksu, Necil Kutukculer

Open access · greenAbstract read
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. B Cell Disorders in Children-Part I.Current allergy and asthma reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Neslihan Edeer KaracaDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Ezgi Ulusoy SevercanDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Burcu GuvenDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Elif AzarsizDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Guzide AksuDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Necil KutukculerDepartment of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey.
Ege University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Transmembrane Activator and Calcium modulator ligand Interactor (TACI), encoded by

methodsForty two CVID, 36 selective IgAD, 34 partial IgAD and 25 healthy controls were included. All patients were examined for

resultsThe percentages of

conclusionModifier genes as well as their combination with other genetic or environmental factors may play an important role in the development of the immunodeficiency phenotype.

Indexed as

Common variable immunodeficiencyIgA deficiencyMutationRespiratory tract infectionTACI

Identifiers

PMID30090215
PMCPMC6064010
OpenAlexW2887623619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.